McKESSON CORPORATION FY 2026 10-K, explained in plain English
Key financials — as reported
| Total revenue | $403.4B |
| Gross margin | 3.6% |
| Operating income | $6.2B |
| Net income | $4.8B |
| Diluted EPS | $38.38 |
| Cash & equivalents | $4.0B |
| Total assets | $82.3B |
| Long-term debt | $6.5B |
Key takeaway
McKesson reorganized into four new reportable segments in fiscal 2026: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions.
🔒 4 more takeaways in the full analysis
Beneath the surface
The company operates with a stockholders' deficit structure implied by accounts payable of $59.97 billion vastly exceeding cash of $3.98 billion, typical of distribution businesses running on supplier float rather than equity.
🔒 4 more insights a headline reader would miss
This is the free preview. The full analysis explains every line item above and includes 8 more findings — plus insider trades, activist stakes, and 8-K events for MCK.
Read the full analysis free Free account · 5 full analyses included · no card required